EU/3/18/2089
Table of contents
About
On 19 November 2018, orphan designation (EU/3/18/2089) was granted by the European Commission to Dystrogen Therapeutics S.A., Poland, for ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor for the treatment of Duchenne muscular dystrophy.
Key facts
Active substance |
Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor
|
Disease / condition |
Treatment of Duchenne muscular dystrophy
|
Date of first decision |
19/11/2019
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2089
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Kasztelanska 49
60-316 Poznan
Poland
Tel. + 48 698 647 783
E-mail: info@dystrogen.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.